Recent Quotes
My Watchlist
Indicators
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bio-Path Holdings (NQ: BPTH )

1.640 -0.150 (-8.38%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 9, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 146,994
Open 1.760
Bid (Size) 1.690 (25)
Ask (Size) 1.800 (5)
Prev. Close 1.790
Today's Range 1.610 - 1.799
52wk Range 0.3200 - 7.670
Shares Outstanding 1,656,235
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Bio-Path Holdings Provides Clinical Update and Expansion Plans
From Bio-Path Holdings, Inc.
Via GlobeNewswire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
It's time to start the day with a breakdown of the biggest pre-market stock movers worth keeping an eye on for Tuesday morning! 
Via InvestorPlace

Performance

YTD
+232.99%
+232.99%
1 Month
-29.00%
-29.00%
3 Month
-57.07%
-57.07%
6 Month
+209.38%
+209.38%
1 Year
+10.07%
+10.07%

More News

Read More
Acute Myeloid Leukemia Market Size Expected to Reach $2.97 Billion By 2029 as Clinical Trials Increase
Via FinancialNewsMedia
Acute Myeloid Leukemia Market Size Expected to Reach $2.97 Billion By 2029 as Clinical Trials Increase
From FN Media Group LLC
Via GlobeNewswire
Onsemi Layoffs 2024: What to Know as Onsemi Cuts 1,000 Jobs
Via InvestorPlace
Topics Workforce
Exposures Layoff
Why Bank of America Thinks Hasbro (HAS) Stock Can Gain 40% From Here
Via InvestorPlace
Why Is Bio-Path (BPTH) Stock Up 20% Today?
Via InvestorPlace
Why Bio-Path Stock Is Climbing Today
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Bio-Path Holdings Presents Data from Ongoing Phase 2 Combination Study of Prexigebersen for Treatment of Acute Myeloid Leukemia at European Hematology Association Congress
From Bio-Path Holdings, Inc.
Via GlobeNewswire
Bio-Path Holdings Announces Closing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
From Bio-Path Holdings, Inc.
Via GlobeNewswire
Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q1 24
Via Newsfile
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Bio-Path Holdings Announces $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
From Bio-Path Holdings, Inc.
Via GlobeNewswire
Dow Dips Over 300 Points; GameStop Shares Spike Higher
Via Benzinga
Topics Stocks
Exposures US Equities
Why Science Applications International Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Crude Oil Down Over 3%; US Construction Spending Falls In May
Via Benzinga
Exposures Fossil Fuels
What's Going On With Bio-Path Stock?
Via Benzinga
Nasdaq Surges 150 Points; US Manufacturing PMI Rises In May
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Bio-Path Holdings Presents Data from Ongoing Phase 2 Combination Study of Prexigebersen for Treatment of Acute Myeloid Leukemia at American Society of Clinical Oncology (ASCO) Annual Meeting
From Bio-Path Holdings, Inc.
Via GlobeNewswire
Bio-Path Holdings to Present Data at 2024 European Hematology Association Congress
From Bio-Path Holdings, Inc.
Via GlobeNewswire
Bio-Path Holdings to Present Data at American Society of Clinical Oncology (ASCO) Annual Meeting
From Bio-Path Holdings, Inc.
Via GlobeNewswire
BPTH Stock Earnings: Bio-Path Holdings Misses EPS for Q1 2024
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.